BMI, Weight-Loss Injections and Who They're Actually For

Originally published December 2025 · Updated April 2026 with the NHS phased rollout criteria, the April 2026 NICE cardiovascular recommendation for semaglutide, and the March 2026 London Health Committee weight loss medication report.

Weight-loss injections have moved from niche clinical treatment to mainstream conversation faster than almost any pharmaceutical development in recent memory. A study published in January 2026 found that across England, Scotland and Wales, 1.6 million people are estimated to have used weight-loss medicines between early 2024 and 2025, and a further 3.3 million said they would be interested in using them in the next year.

The volume of interest has outpaced the public understanding of what these medications are for, who they are designed for, and what happens when they are used outside their intended clinical purpose. This article covers all of it.

TL;DR

• Mounjaro (tirzepatide) and Wegovy (semaglutide) are NHS-approved weight management medications for people with obesity and weight-related health conditions — not cosmetic weight loss tools.
• NHS England's current Mounjaro criteria begin with BMI 40 or above with four qualifying health conditions — with a phased rollout broadening to BMI 35 with four conditions from around June 2026 and BMI 40 with three conditions from March 2027.
• Wegovy requires BMI 35 or above, or 32.5 or above for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, with at least one weight-related health condition.
• Ethnic BMI adjustments are built into NHS criteria — evidence shows higher cardiometabolic risk at lower BMI in certain ethnic groups.
• Using these medications at a normal or low BMI carries genuine medical risks including muscle loss, hormonal disruption, and nutritional deficiency.
• Private prescribers apply lower thresholds — typically BMI 27 or above with a health condition — which is within the medicines' licensed range but significantly broader than NHS criteria.

Why BMI Is Used in Weight-Loss Prescribing

Body Mass Index is an imperfect but widely used clinical screening tool. It relates weight to height and provides a practical population-level estimate of health risk associated with excess body fat.

BMI does not capture body composition, fat distribution, or metabolic health in full detail. It does not distinguish between muscle and fat, and it does not account for differences related to age, sex, fitness level, or ethnicity. A lean athlete with high muscle mass and a person with high visceral fat can have identical BMIs. These are genuine limitations.

Despite these limitations, BMI remains embedded in weight management prescribing because it provides a consistent, reproducible, and clinically validated starting point for risk stratification. Weight-loss medications affect appetite, digestion, and metabolism across multiple organ systems — they carry real risks. The benefit-risk calculation requires an estimate of how significant the weight-related health burden is, and BMI, alongside clinical markers, provides that estimate.

In straightforward terms: these medications are reserved for people where the documented health risks of excess weight outweigh the risks of the treatment itself. BMI is part of how that threshold is assessed.

The NHS Criteria in 2026: What They Actually Are

The NHS has implemented a phased rollout of Mounjaro and Wegovy, with eligibility criteria set by NICE and managed through NHS England's commissioning guidance. The criteria are considerably stricter than private prescribing thresholds — and are designed to reach those with the highest clinical need first.

Mounjaro (Tirzepatide) on the NHS

From 23 March 2025, Mounjaro became available through specialist weight management services and, in a phased rollout, through GP surgeries and community clinics. Initially, eligibility is restricted to people with a BMI of 40 or above with four qualifying health conditions. From around June 2026, criteria are expected to broaden to include people with a BMI of 35 or above with four qualifying conditions. From March 2027, the threshold may shift again to BMI 40 or above with three conditions.

The qualifying health conditions include type 2 diabetes, high blood pressure, high cholesterol, heart disease, sleep apnoea, and other obesity-related conditions.

NHS patients prescribed Mounjaro must concurrently attend a wraparound care programme — providing behavioural support, dietary guidance, and physical activity support alongside the medication. The medication alone is not the treatment; the programme is.

NHS England plans to roll Mounjaro out to 220,000 people by the end of 2025, with half a million Londoners estimated to ultimately qualify. The rollout is still in early stages — as of early 2026, only a small fraction of eligible patients have been able to access it through NHS pathways, with waiting lists at specialist services often stretching to years.

Wegovy (Semaglutide) on the NHS

Wegovy requires a BMI of 35 or above, or 32.5 or above if you are from a South Asian, Chinese, Middle Eastern, Black African or African-Caribbean background, along with at least one weight-related health condition. For people with a lower BMI — 30 to 34.9, or 27.5 to 32.4 for those from the ethnic groups above — eligibility requires meeting additional criteria for specialist weight management service referral.

Wegovy is only available through specialist weight management services — not through GP prescription. It is the only weight-loss injection approved for people with established cardiovascular disease and excess weight.

In April 2026, NICE recommended semaglutide alongside a reduced-calorie diet and increased physical activity to lower the risk of heart attack, stroke, or dying from heart disease in people with a BMI of 27 or above who have established cardiovascular disease. This represents a significant expansion of the cardiovascular indication — effectively broadening Wegovy's clinical use beyond weight management into secondary cardiovascular prevention.

The Ethnic BMI Adjustment: Why It Matters

One of the most clinically important features of the NHS criteria is the ethnic BMI adjustment — and it is one of the least understood.

For individuals from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, BMI thresholds are reduced by 2.5 kg/m² across all eligibility criteria.

This adjustment reflects a well-documented finding in epidemiological research: people from these ethnic backgrounds face significantly higher cardiometabolic risk — including type 2 diabetes, cardiovascular disease, and metabolic syndrome — at lower BMI values than white European populations. The biological mechanisms involve differences in fat distribution, with higher levels of visceral fat at equivalent BMI values in South and East Asian populations compared to white Europeans.

In practical terms: a South Asian person with a BMI of 32.5 and type 2 diabetes has equivalent clinical risk to a white European person with a BMI of 35 and type 2 diabetes, and the NHS criteria reflect this equivalence. BMI is not a culturally neutral tool, and the adjustments acknowledge that.

Private Prescribing: A Different Threshold

Private providers operate to the medicines' licensed indications rather than NHS commissioning criteria — which are stricter than the licence specifically to manage NHS budget and prioritise those at highest clinical need.

For private treatment, Wegovy may be suitable for people with a BMI of 30 or higher, or 27 or higher with weight-related health conditions. Mounjaro thresholds for private prescribing are similar.

This means a significant population — people with a BMI between 27 and 35 with metabolic risk factors — can access these medications privately but not on the NHS. This is not a failure of the private system; it reflects the difference between what is clinically appropriate for an individual and what can be prioritised across a national healthcare budget.

The private market has expanded rapidly alongside NHS rollout. The existence of this two-tier system underlines the urgency of increasing NHS availability of weight-loss drugs in order to prevent a growth of unequal health outcomes, while ensuring patients receive a high standard of care.

What the private route does not change is the fundamental clinical principle: these medications require a proper medical assessment, clinical oversight, and concurrent lifestyle support to be used safely and effectively. Any provider offering these medications without a full medical history review is operating outside safe prescribing standards.

What Happens When These Medications Are Used at a Low BMI

This is where the clinical concern is most acute — and the section of this topic that social media coverage most consistently ignores.

Weight-loss injections work by suppressing appetite and slowing gastric emptying. In people with excess weight and metabolic dysfunction, this produces meaningful health improvements. In people without excess weight, the same mechanisms produce a different and concerning set of outcomes.

Caloric Deficit Without Appropriate Fat Stores

When appetite is suppressed in a person whose body fat is at or below the healthy range, the body cannot draw primarily on fat for energy. Weight loss at a low BMI is more likely to come from lean tissue — muscle — rather than fat, which compromises long-term metabolic health, physical function, and overall resilience.

Muscle tissue is not a passive energy reserve. It plays a central role in glucose regulation, metabolic rate, immune function, balance, mobility, and long-term independence. Muscle loss is harder to reverse than fat gain and has consequences that extend well beyond aesthetics.

Nutritional Deficiency

Suppressed appetite does not discriminate between calories. Reduced food intake means reduced intake of protein, vitamins, and minerals — with particular risks of protein deficiency, iron deficiency, B12 deficiency, and calcium deficiency at sustained low intake. These deficiencies compound over time and are not immediately visible.

Hormonal Disruption

Chronic under-fuelling disrupts multiple hormonal axes. In women, significant caloric restriction suppresses oestrogen production, can disrupt menstrual cycles, and affects bone mineral density. In men, it suppresses testosterone. Leptin — the satiety hormone — declines with weight loss in ways that drive increased hunger and reduced metabolic rate, creating a physiological state that is difficult to sustain.

Psychological Risk

Weight-loss medications also influence eating behaviour and reward pathways at a neurological level. In people without clinical need for weight loss, appetite suppression can reinforce restrictive eating patterns, increase food-related anxiety, and in people with existing vulnerability, contribute to disordered eating. These are not theoretical concerns — they are recognised in the clinical literature on off-label GLP-1 use.

BMI Alone Is Not the Full Picture

It is worth acknowledging one important nuance: some people have significant metabolic dysfunction at a normal BMI. Insulin resistance, non-alcoholic fatty liver disease, visceral adiposity without high overall body weight, and other metabolic conditions can exist in people whose BMI does not flag clinical concern.

For these individuals, the appropriate intervention is rarely appetite-suppressing medication. It is typically dietary quality improvement — reducing ultra-processed food, improving fibre intake, stabilising blood sugar — alongside resistance exercise to improve insulin sensitivity and preserve muscle mass. These approaches address the underlying metabolic issue without the risks associated with appetite suppression in someone who does not need to lose weight.

Frequently Asked Questions

What BMI do you need for weight loss injections on the NHS?

NHS criteria vary by medication and are being phased in over time. For Mounjaro, current eligibility begins at BMI 40 or above with four qualifying health conditions through specialist services, broadening to BMI 35 with four conditions from around June 2026. For Wegovy, the threshold is BMI 35 or above with at least one weight-related health condition, or lower with specialist service referral. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, all thresholds are reduced by 2.5 BMI points.

Can I get weight loss injections privately at a lower BMI?

Private prescribing follows the medicines' licensed indications rather than NHS criteria. Wegovy and Mounjaro can be prescribed privately to people with a BMI of 27 or above with weight-related health conditions. A proper medical assessment is required regardless of the prescribing route — any provider offering these medications without a full clinical consultation should be avoided. Look for GPhC-registered or CQC-registered providers with GMC-registered prescribers.

Why are BMI thresholds lower for some ethnic groups?

Research consistently shows that people from South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds face higher cardiometabolic risk — including type 2 diabetes and cardiovascular disease — at lower BMI values than white European populations. This reflects differences in body fat distribution, particularly higher visceral fat at equivalent BMI. NHS criteria reduce BMI thresholds by 2.5 kg/m² for these groups to reflect equivalent clinical risk rather than equivalent BMI.

What are the risks of using weight loss injections at a normal or low BMI?

The primary risks are muscle loss — because the body cannot draw primarily on fat when fat stores are limited — and nutritional deficiency from sustained reduced caloric intake. Hormonal disruption, including menstrual irregularity in women and reduced testosterone in men, is also a concern. Psychologically, appetite suppression in people without clinical need for weight loss can reinforce restrictive eating patterns and increase food-related anxiety. These risks are disproportionate in the absence of obesity-related health conditions because there is no meaningful clinical benefit to offset them.

Are weight loss injections suitable for people who want to lose a small amount of weight?

No — these medications are designed for people with obesity and weight-related health conditions where the health risks of excess weight outweigh the risks of the treatment. Using them for cosmetic or minor weight reduction in people without clinical indication exposes them to real physiological risks without a meaningful health benefit. For people in the healthy BMI range looking to improve their relationship with food or address metabolic markers, dietary quality approaches — such as those covered in the Sugar Reset and Junk Food Reset — are safer and more appropriate.

Will I regain weight when I stop weight loss injections?

Most people regain significant weight when they stop these medications without sustained lifestyle changes. A 2026 BMJ meta-analysis of 37 studies found that people who stopped newer weight-loss medicines regained a substantial portion of lost weight within a year. This is why the NHS requires concurrent wraparound care — the medication is one component of a broader programme that includes dietary and behavioural support, not a standalone intervention.

The Bottom Line

Weight-loss injections are a genuine and significant clinical advance for people with obesity and weight-related health conditions. The NHS criteria — though strict and currently reaching only a fraction of eligible patients — reflect a considered benefit-risk assessment based on where the evidence of clinical benefit is strongest.

Using these medications outside their intended clinical purpose — particularly in people with a normal or low BMI — exposes individuals to real physiological risks without meaningful health benefit. The growing private market has made access easier, but easier access does not mean appropriate use for everyone who can obtain them.

For people in the healthy BMI range looking to improve metabolic health, energy, and dietary habits without appetite suppression, the Sugar Reset and Junk Food Reset from the Reset Series™ address the underlying dietary patterns that drive metabolic dysfunction — without the risks of unnecessary appetite suppression. The Reset Companion can also help you stay consistent with the behavioural side of these protocols.

Related reading: Weight Loss Injections UK 2026: Mounjaro vs Wegovy vs Ozempic Compared · GLP-1 Drugs and Liver Health: What the Research Shows · The Keto Diet: Who It Actually Works For — and Who It Doesn't

Popular Articles